PT - JOURNAL ARTICLE AU - Shinya Tsuzuki AU - Kayoko Hayakawa AU - Yukari Uemura AU - Tomohiro Shinozaki AU - Nobuaki Matsunaga AU - Mari Terada AU - Setsuko Suzuki AU - Hiroshi Ohtsu AU - Yusuke Asai AU - Koji Kitajima AU - Sho Saito AU - Gen Yamada AU - Taro Shibata AU - Masashi Kondo AU - Kazuo Izumi AU - Masayuki Hojo AU - Tetsuya Mizoue AU - Kazuhisa Yokota AU - Fukumi Nakamura-Uchiyama AU - Fumitake Saito AU - Wataru Sugiura AU - Norio Ohmagari TI - Efficacy of remdesivir in hospitalised COVID-19 patients in Japan: A large observational study using the COVID-19 Registry Japan AID - 10.1101/2021.03.09.21253183 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.09.21253183 4099 - http://medrxiv.org/content/early/2021/09/06/2021.03.09.21253183.short 4100 - http://medrxiv.org/content/early/2021/09/06/2021.03.09.21253183.full AB - Objectives Although several randomised controlled trials have compared the efficacy of remdesivir with that of placebo, there is limited evidence regarding its effect in the early stage of nonsevere COVID-19 cases.Methods We evaluated the efficacy of remdesivir on the early stage of nonsevere COVID-19 using the COVID-19 Registry Japan, a nationwide registry of hospitalised COVID-19 patients in Japan. Two regimens (start remdesivir therapy within 4 days from admission vs. no remdesivir during hospitalisation) among patients without the need for supplementary oxygen therapy were compared by a three-step processing (cloning, censoring, and weighting) method. The primary outcome was supplementary oxygen requirement during hospitalisation. Secondary outcomes were 30-day fatality risk and risk of invasive mechanical ventilation or extracorporeal membrane oxygenation (IMV/ECMO).Results The data of 12,657 cases met our inclusion criteria. The ‘start remdesivir’ regimen showed a lower risk of supplementary oxygen requirement (hazard ratio: 0.861, p < 0.001). Both 30-day fatality risk and risk of IMV/ECMO introduction were not significantly different between the two regimens (hazard ratios: 1.05 and 0.886, p values: 0.070 and 0.440, respectively).Conclusions Remdesivir might reduce the risk of oxygen requirement during hospitalisation in the early stage of COVID-19; however, it had no positive effect on the clinical outcome and reduction of IMV/ECMO requirement.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Health and Labour Sciences Research Grant, Research for risk assessment and implementation of crisis management functions for emerging and re-emerging infectious diseases (19HA1003).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the NCGM ethics review board (NCGM-G-003494-0).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this study would be available upon a reasonable request to the corresponding author.